1. Clinical Overview
Linagliptin is a potent, selective, competitive dipeptidyl peptidase-4 (DPP-4) inhibitor used for the treatment of type 2 diabetes mellitus. It is a xanthine-based oral anti-diabetic agent that increases the concentration of active incretin hormones (GLP-1 and GIP), thereby increasing insulin secretion and decreasing glucagon secretion in a glucose-dependent manner. Its unique pharmacokinetic profile allows for a once-daily, 5mg dose without adjustment for renal or hepatic impairment.
| Onset | Duration | Bioavailability |
|---|---|---|
| Within 1-2 hours for DPP-4 enzyme inhibition. | Approximately 24 hours, supporting once-daily dosing. | Approximately 30%. |
2. Mechanism of Action
Linagliptin selectively and competitively inhibits the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 rapidly degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, linagliptin increases and prolongs the activity of these endogenous incretins.
3. Indications & Uses
- Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Monotherapy when metformin is contraindicated or not tolerated.
4. Dosage & Administration
Adult Dosage: 5 mg once daily, with or without food.
Administration: Tablet to be swallowed whole with a glass of water. Can be taken at any time of the day, but preferably at the same time each day to maintain routine.
5. Side Effects
Common side effects may include:
- Nasopharyngitis
- Headache
- Hypoglycemia (especially when used with sulfonylureas or insulin)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Strong CYP3A4 or P-gp Inducers (e.g., Rifampicin, Carbamazepine, Phenytoin) | May decrease linagliptin plasma concentrations. Monitor glycemic control. | Moderate |
| Sulfonylureas (e.g., Glimepiride, Glipizide) or Insulin | Increased risk of hypoglycemia. May require dose reduction of sulfonylurea/insulin. | Moderate |
| Loop Diuretics (e.g., Furosemide) | Potential pharmacodynamic interaction increasing blood glucose. Monitor. | Minor |
7. Patient Counselling
- DO take the tablet once daily as prescribed, even if you feel well.
- DO continue your diet and exercise plan.
- DO inform all your doctors and pharmacists you are taking this medicine.
- DONT skip meals, especially when also taking sulfonylureas or insulin.
- DONT crush or chew the tablet.
8. Toxicology & Storage
Overdose: In clinical studies, doses up to 600 mg were administered and were well-tolerated. Expected symptoms in massive overdose could include hypoglycemia, headache, and GI disturbances.
Storage: Store below 30°C. Protect from light and moisture. Keep the blister strips in the outer carton. Keep out of reach of children.